Literature DB >> 17040410

Serotonin transporter gene polymorphism and irritable bowel syndrome.

J M Park1, M-G Choi, J-A Park, J H Oh, Y K Cho, I S Lee, S W Kim, K Y Choi, I-S Chung.   

Abstract

Polymorphisms in the promoter region of the serotonin reuptake transporter (SERT) gene may underlie the disturbance in gut function in patients with irritable bowel syndrome (IBS). Association studies of SERT polymorphisms and IBS have shown diverse results among different countries, which might be due to racial and subject composition differences. The aim of this study was to assess the potential association between SERT polymorphisms and IBS in Koreans. A total of 190 IBS patients, who met the Rome II criteria, and 437 healthy controls were subjected to genotyping. SERT polymorphisms differed in the IBS and control groups (P = 0.014). The SERT deletion/deletion genotype occurred with greater frequency in the diarrhoea-predominant IBS group than in the controls. A strong genotypic association was observed between the SERT deletion/deletion genotype and diarrhoea-predominant IBS (P = 0.012). None of the clinical symptoms analysed was significantly associated with the SERT genotypes. The frequency of the SERT insertion/insertion genotype was much lower than that of the other two genotypes. A significant association was observed between the SERT polymorphism and IBS, especially diarrhoea-predominant IBS, suggesting that the SERT gene is a potential candidate gene involved in IBS in Korea.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17040410     DOI: 10.1111/j.1365-2982.2006.00829.x

Source DB:  PubMed          Journal:  Neurogastroenterol Motil        ISSN: 1350-1925            Impact factor:   3.598


  32 in total

1.  Genetic polymorphism of pri-microRNA 325, targeting SLC6A4 3'-UTR, is closely associated with the risk of functional dyspepsia in Japan.

Authors:  Tomiyasu Arisawa; Tomomitsu Tahara; Tomoki Fukuyama; Ranji Hayashi; Kazuhiro Matsunaga; Nobuhiko Hayashi; Masakatsu Nakamura; Nobuyuki Toshikuni; Hisakazu Shiroeda; Tomoyuki Shibata
Journal:  J Gastroenterol       Date:  2012-03-22       Impact factor: 7.527

Review 2.  Genetic approaches to functional gastrointestinal disorders.

Authors:  Yuri A Saito; Nandita Mitra; Emeran A Mayer
Journal:  Gastroenterology       Date:  2010-02-19       Impact factor: 22.682

Review 3.  Pharmacogenetics and the treatment of functional gastrointestinal disorders.

Authors:  Houssam Halawi; Michael Camilleri
Journal:  Pharmacogenomics       Date:  2017-07-07       Impact factor: 2.533

4.  Trauma history and risk of the irritable bowel syndrome in women veterans.

Authors:  D L White; L S Savas; K Daci; R Elserag; D P Graham; S J Fitzgerald; S L Smith; G Tan; H B El-Serag
Journal:  Aliment Pharmacol Ther       Date:  2010-06-04       Impact factor: 8.171

5.  Serotonin transporter and G protein beta 3 subunit gene polymorphisms in Greeks with irritable bowel syndrome.

Authors:  T Markoutsaki; T Karantanos; M Gazouli; N P Anagnou; S D Ladas; D G Karamanolis
Journal:  Dig Dis Sci       Date:  2011-05-11       Impact factor: 3.199

6.  Non-invasive brain stimulation approaches to fibromyalgia pain.

Authors:  Baron Short; Jeffrey J Borckardt; Mark George; Will Beam; Scott T Reeves
Journal:  J Pain Manag       Date:  2009-01-01

Review 7.  Pathophysiology of fibromyalgia.

Authors:  Laurence A Bradley
Journal:  Am J Med       Date:  2009-12       Impact factor: 4.965

8.  The serotonin transporter polymorphism rs25531 is associated with irritable bowel syndrome.

Authors:  Ruth Kohen; Monica E Jarrett; Kevin C Cain; Sang-Eun Jun; Grace P Navaja; Sarah Symonds; Margaret M Heitkemper
Journal:  Dig Dis Sci       Date:  2009-12       Impact factor: 3.199

Review 9.  Serotonin in the gastrointestinal tract.

Authors:  Michael Camilleri
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2009-02       Impact factor: 3.243

10.  Polymorphism in the oxytocin promoter region in patients with lactase non-persistence is not related to symptoms.

Authors:  Mikael Truedsson; Joyce Carlson; Magnus Simrén; Bodil Ohlsson
Journal:  BMC Gastroenterol       Date:  2009-11-30       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.